Research Progress on Prognosis of Children with Autoimmune Epilepsy Encephalopathy

doi:10.12114/j.issn.1007-9572.2021.00.485

Abstract

Abstract: Autoimmune epileptic encephalopathy（AEE） is a potentially treatable neurological disease.It usually refers to acute or subacute seizures that occur in the presence of encephalopathy.The neuronal targets of autoimmune epilepsy encephalopathy related to children mainly include NMDA receptor，GABA receptor，LGI1 receptor，AMPA receptor，glycine receptor，MOG and so on.At present，the main prognosis of children's AEE is through the modified Rankin Scale（mRS） and Pediatric Cerebral Performance Category（PCPC）.According to the scale evaluation，85% of the children have a good prognosis，but some studies have shown that some children have sequelae such as decreased learning ability，cognitive impairment，and social impairment，but there is no obvious manifestation in the scale.This article will review the latest research progress in children's AEE prognosis，aiming to provide a theoretical basis for clinicians' early follow-up，identification and prevention.

Key words: Autoimmune epilepsy, Epilepsy, Brain diseases, Prognosis, Review

摘要： 自身免疫性癫痫脑病（AEE）是一种潜在的、可治疗的神经系统疾病。其通常指在有脑病的情况下发作的急性或亚急性癫痫。与儿童有关的AEE的神经元靶点主要有NMDA受体、GABA受体、LGI1受体、AMPA受体、甘氨酸受体、MOG等。目前判断儿童AEE预后主要是通过改良的Rankin量表（mRS）和儿童脑功能分类量表（PCPC）。通过量表评估85%的患儿有良好的预后，但有研究显示有一部分患儿存在学习能力下降、认知障碍及社交障碍等后遗症，然而在量表中没有明显的体现。本文将对儿童AEE预后方面的最新研究进展做综述，旨在为临床医师早期随访、识别及预防提供一定的理论基础。

关键词: 自身免疫性癫痫, 癫痫, 脑疾病, 预后, 综述

ZHANG Kai,LU Hongru,SUN Suzhen. Research Progress on Prognosis of Children with Autoimmune Epilepsy Encephalopathy　[J]. Chinese General Practice, 2021, 24(20): 2619-2623. DOI: 10.12114/j.issn.1007-9572.2021.00.485.
张凯,卢红茹,孙素真. 儿童自身免疫性癫痫脑病预后的研究进展[J]. 中国全科医学, 2021, 24(20): 2619-2623. DOI: 10.12114/j.issn.1007-9572.2021.00.485.

References

［1］WRIGHT S，VINCENT A.Pediatric autoimmune epileptic encephalopathies［J］．J Child Neurol，2017，32（4）：418-428．DOI：10.1177/0883073816685505.
［2］DUBEY D，SINGH J，BRITTON J W，et al．Predictive models in the diagnosis and treatment of autoimmune epilepsy［J］．Epilepsia，2017，58（7）：1181-1189．DOI：10.1111/epi.13797.
［3］DALMAU J，TüZüN E，WU H Y，et al．Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma［J］．Ann Neurol，2007，61（1）：25-36．DOI：10.1002/ana.21050.
［4］KAYSER M S，DALMAU J.Anti-NMDA receptor encephalitis，autoimmunity，and psychosis［J］．Focus （Am Psychiatr Publ），2016，14（4）：510-515．DOI：10.1176/appi.focus.140405.
［5］FUNAYAMA M，MIZUSHIMA J，TAKATA T，et al．Altered perception might be a symptom of anti-N-methyl-D-aspartate receptor （NMDAR） encephalitis［J］．Neurocase，2018，24（5/6）：255-258．DOI：10.1080/13554794.2019.1573260.
［6］ARMANGUE T，SPATOLA M，VLAGEA A，et al．Frequency，symptoms，risk factors，and outcomes of autoimmune encephalitis after Herpes simplex encephalitis：a prospective observational study and retrospective analysis［J］．Lancet Neurol，2018，17（9）：760-772．DOI：10.1016/s1474-4422（18）30244-8.
［7］HéBERT J，DAY G S，STERIADE C，et al．Long-term cognitive outcomes in patients with autoimmune encephalitis［J］．Can J Neurol Sci，2018，45（5）：540-544．DOI：10.1017/cjn.2018.33.
［8］陈向军，邓波.自身免疫性脑炎的诊断标准及其临床指导意义［J］．中国临床神经科学，2016，24（3）：336-340.　CHEN X J，DENG B.Clinical diagnostic criteria for autoimmune encephalitis and its implication on treatment［J］．Chin J Clin Neurosci，2016，24（3）：336-340.
［9］SULEIMAN J，DALE R C.The recognition and treatment of autoimmune epilepsy in children［J］．Dev Med Child Neurol，2015，57（5）：431-440．DOI：10.1111/dmcn.12647.
［10］QUINN T J，DAWSON J，WALTERS M R，et al．Reliability of the modified Rankin Scale：a systematic review［J］．Stroke，2009，40（10）：3393-3395．DOI：10.1161/STROKEAHA.109.557256.
［11］POLLACK M M，HOLUBKOV R，FUNAI T，et al．Relationship between the functional status scale and the pediatric overall performance category and pediatric cerebral performance category scales［J］．JAMA Pediatr，2014，168（7）：671-676．DOI：10.1001/jamapediatrics.2013.5316.
［12］ZWART R，SHER E，PING X，et al．Perampanel，an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors，for the treatment of epilepsy：studies in human epileptic brain and nonepileptic brain and in rodent models［J］．J Pharmacol Exp Ther，2014，351（1）：124-133．DOI：10.1124/jpet.114.212779.
［13］孙梦娇，马莉花，陈莉，等．自身免疫性脑炎诊断及治疗研究新进展［J］．中国全科医学，2018，21（11）：1368-1371.
SUN M J，MA L H，CHEN L，et al．New advances in the diagnosis and treatment of autoimmune encephalitis［J］．Chin Gen Pract，2018，21（11）：1368-1371.
［14］DHAWAN S R，SANKHYAN N.Low-dose rituximab in children with anti-NMDAR encephalitis［J］．Pediatr Neurol，2018，87：82．DOI：10.1016/j.pediatrneurol.2018.07.006.
［15］LIU X，ZHANG L，CHEN C，et al．Long-term cognitive and neuropsychiatric outcomes in patients with anti-NMDAR encephalitis［J］．Acta Neurol Scand，2019，140（6）：414-421．DOI：10.1111/ane.13160.
［16］GUO Y Y，Lü X Y，WU Y，et al．Cognitive function and cerebral blood perfusion changes in patients with anti-N-methyl-D-aspartate receptor encephalitis［J］．Zhonghua Yi Xue Za Zhi，2020，100（25）：1942-1946．DOI：10.3760/cma.j.cn112137-20200108-00050.
［17］DE BRUIJN M A A M，AARSEN F K，VAN OOSTERHOUT M P，et al．Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis［J］．Neurology，2018，90（22）：e1997-2005．DOI：10.1212/wnl.0000000000005605.
［18］BALU R，MCCRACKEN L，LANCASTER E，et al．A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis［J］．Neurology，2019，92（3）：e244-252．DOI：10.1212/wnl.0000000000006783.
［19］QUEK A M L，O'TOOLE O.Autoimmune epilepsy：the evolving science of neural autoimmunity and its impact on epilepsy management［J］．Semin Neurol，2018，38（3）：290-302．DOI：10.1055/s-0038-1660860.
［20］MANDEL-BREHM C，DUBEY D，KRYZER T J，et al．Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis［J］．N Engl J Med，2019，381（1）：47-54．DOI：10.1056/NEJMoa1816721.
［21］MAUREILLE A，FENOUIL T，JOUBERT B，et al．Isolated seizures are a common early feature of paraneoplastic anti-GABA_B receptor encephalitis［J］．J Neurol，2019，266（1）：195-206．DOI：10.1007/s00415-018-9132-0.
［22］DE BRUIJN M A A M，VAN SONDEREN A，VAN COEVORDEN-HAMEETE M H，et al．Evaluation of seizure treatment in anti-LGI1，anti-NMDAR，and anti-GABABR encephalitis［J］．Neurology，2019，92（19）：e2185-2196．DOI：10.1212/WNL.0000000000007475.
［23］SPATOLA M，PETIT-PEDROL M，SIMABUKURO M M，et al．Investigations in GABAA receptor antibody-associated encephalitis［J］．Neurology，2017，88（11）：1012-1020．DOI：10.1212/wnl.0000000000003713.
［24］LIN J F，LI C，LI A Q，et al．Encephalitis with antibodies against the GABAB receptor：high mortality and risk factors［J］．Front Neurol，2019，10：1030．DOI：10.3389/fneur.2019.01030.
［25］CAPUTO D，IORIO R，VIGEVANO F，et al．Febrile infection-related epilepsy syndrome （FIRES） with super-refractory status epilepticus revealing autoimmune encephalitis due to GABAAR antibodies［J］．Eur J Paediatr Neurol，2018，22（1）：182-185．DOI：10.1016/j.ejpn.2017.11.005.
［26］O'CONNOR K，WATERS P，KOMOROWSKI L，et al．GABAA receptor autoimmunity：a multicenter experience［J］．Neurol Neuroimmunol Neuroinflamm，2019，6（3）：e552．DOI：10.1212/NXI.0000000000000552.
［27］ARI?O H，ARMANGUé T，PETIT-PEDROL M，et al．Anti-LGI1-associated cognitive impairment：presentation and long-term outcome［J］．Neurology，2016，87（8）：759-765．DOI：10.1212/WNL.0000000000003009.
［28］SALAMA S，KHAN M，PARDO S，et al．MOG antibody-associated encephalomyelitis/encephalitis［J］．Mult Scler，2019，25（11）：1427-1433．DOI：10.1177/1352458519837705.
［29］MALAGON V J．［Demyelinizing diseases in children.Acute disseminated encephalomyelitis and multiple sclerosis］［J］．Medicina （B Aires），2019，79 Suppl 3：66-70.
［30］POHL D，ALPER G，VAN HAREN K，et al．Acute disseminated encephalomyelitis：updates on an inflammatory CNS syndrome［J］．Neurology，2016，87（9 suppl 2）：S38-45．DOI：10.1212/wnl.0000000000002825.
［31］OUMERZOUK J，ABIDA N，BOURAZZA A，et al．Radiological and etiological features of acute disseminated encephalomyelitis in adults［J］．Press Med Paris France，2019，48（12）：1569-1573．DOI：10.1016/j.lpm.2019.10.018.
［32］HACOHEN Y，WONG Y Y，LECHNER C，et al．Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease［J］．JAMA Neurol，2018，75（4）：478-487．DOI：10.1001/jamaneurol.2017.4601.
［33］PRADHAN S，DAS A.Gray variant of acute disseminated encephalomyelitis and its response to immunomodulatory drugs［J］．Neurol India，2019，67（1）：284-286．DOI：10.4103/0028-3886.253652.
［34］HAHN C D，MILES B S，MACGREGOR D L，et al．Neurocognitive outcome after acute disseminated encephalomyelitis［J］．Pediatr Neurol，2003，29（2）：117-123．DOI：10.1016/s0887-8994（03）00143-7.
［35］DUIGNAN S，WRIGHT S，ROSSOR T，et al．Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes［J］．Dev Med Child Neurol，2018，60（9）：958-962．DOI：10.1111/dmcn.13703.
［36］HAMID S H M，WHITTAM D，SAVIOUR M，et al．Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease［J］．JAMA Neurol，2018，75（1）：65-71．DOI：10.1001/jamaneurol.2017.3196.
［37］ROSSOR T，BENETOU C，WRIGHT S，et al．Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis［J］．Mult Scler，2020，26（3）：333-342．DOI：10.1177/1352458518823486.
［38］GASPARD N，HIRSCH L J，SCULIER C，et al．New-onset refractory status epilepticus （NORSE） and febrile infection-related epilepsy syndrome （FIRES）：state of the art and perspectives［J］．Epilepsia，2018，59（4）：745-752．DOI：10.1111/epi.14022.
［39］GASPARD N，FOREMAN B P，ALVAREZ V，et al．New-onset refractory status epilepticus：etiology，clinical features，and outcome［J］．Neurology，2015，85（18）：1604-1613．DOI：10.1212/WNL.0000000000001940.
［40］JAFARPOUR S，HODGEMAN R M，DE MARCHI CAPELETTO C，et al．New-onset status epilepticus in pediatric patients：causes，characteristics，and outcomes［J］．Pediatr Neurol，2018，80：61-69．DOI：10.1016/j.pediatrneurol.2017.11.016.

[1]	ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129.
[2]	ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117.
[3]	MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102.
[4]	YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779.
[5]	YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790.
[6]	SHI Xiaoqi, LUO Nandu, HUANG Jiaojiao, DU Zuochen, HUANG Pei, CAO Xiuli, CHEN Yan, HE Zhixu. Correlation between Aspartate Aminotransferase/Alanine Aminotransferase and Prognosis of Hemophagocytic Lymphohistiocytosis in Children [J]. Chinese General Practice, 2023, 26(30): 3801-3808.
[7]	TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348.
[8]	BAI Yanmin, DU Kaixian, CHEN Hao, JIA Tianming, GONG Huan, YU Shengyuan, LI Lin, GUAN Jing, ZHU Yingying. Effect of Sodium Valproate, Oxcarbazepine and Levetiracetam on the Development of Different Functional Areas in Children with Epilepsy by Griffiths Development Scales-Chinese Edition [J]. Chinese General Practice, 2023, 26(23): 2918-2922.
[9]	SUN Shuaigang, SHENG Xiaoxiao, ZHANG Wenhui, TIAN Huijuan, ZHAI Yaling. The Analysis of Clinicopathological Characters and Short-term Prognosis in Idiopathic Membranous Nephropathy Patients with Immunoglobulin G4 Combined with Other Different Immunoglobulin G Subtypes Deposition [J]. Chinese General Practice, 2023, 26(21): 2632-2638.
[10]	ZHAO Zewei, KANG Ning, GUO Fengli, WANG Zhongyu, ZHENG Xiangqian. Effect of Aurora Kinase A Expression on Biochemical Cure in Patients after Medullary Thyroid Cancer Resection [J]. Chinese General Practice, 2023, 26(20): 2508-2512.
[11]	ZHANG Kang, JI Wenshuai, KONG Xinxin, DU Chen, XIE Kai, WANG Haifeng. Predictive Efficacies of SOFA Score, CURB-65 Score and PSI Score for 28-day Mortality in Patients with Severe Pneumonia: a Comparative Study [J]. Chinese General Practice, 2023, 26(18): 2217-2222,2226.
[12]	WANG Jun, WU Jiafei, WANG Yijing, ZHENG Boyue, WANG Yu, JIANG Chuanyan, LI Hui. Efficacy and Prognostic Effect of Daratumumab-based Chemotherapy Regimen in Multiple Myeloma: a Real-world Study [J]. Chinese General Practice, 2023, 26(18): 2256-2262.
[13]	XUE Jingru, SUN Suzhen. Clinical Characteristics and Risk Factors for Unfavourble Prognosis of Mycoplasma Pneumoniae Encephalitis in Children [J]. Chinese General Practice, 2023, 26(17): 2125-2131.
[14]	MA Yong, GAO Weibo, ZHU Jihong. Risk Factors of Thrombocytopenia Caused by Pyogenic Liver Abscess [J]. Chinese General Practice, 2023, 26(17): 2120-2124.
[15]	WANG Haiyan, HUANG Yuan, GUI Chun. The Effect of Type 2 Diabetes Mellitus on the Prognosis of Patients with Dilated Cardiomyopathy [J]. Chinese General Practice, 2023, 26(15): 1840-1846.